| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
|
|
|
|||||||
|
|||||||||
| ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Departments of
*
Surgery and
Urology, Duke University Medical Center, Durham, NC 27710
A key and limiting step in the process of generating human monocyte-derived dendritic cells (DC) for clinical applications is maturation. In the setting of immunotherapy, DC are matured ex vivo by culturing them with various agents that mimic the conditions encountered at a site of inflammation. This study examined whether the ex vivo DC maturation step could be replaced by maturing DC in situ by injecting immature DC into sites pre-exposed to agents that induce a microenvironment conducive to in situ maturation of the injected DC. The hypothesis was that recapitulation of the physiological conditions occurring during pathogen infection would lead to optimal conditions for DC maturation, migration, and function. Murine immature DC injected into adjuvant (Adjuprime, poly-arginine, or Imiquimod)-pretreated skin exhibited lymph node migratory capacity comparable to and immunostimulatory capacity equal to or exceeding that of ex vivo matured DC. Acquisition of migratory capacity did not always correlate with enhanced immunostimulatory capacity. Immunostimulatory capacity was not enhanced when mature DC were injected into adjuvant-pretreated sites and remained below that seen with immature DC matured in situ. Immature DC injected into adjuvant-pretreated sites were more effective than mature DC in stimulating antitumor immunity in mice. 111Indium-labeled human monocyte-derived immature DC injected into adjuvant (Imiquimod)-pretreated sites in cancer patients acquired lymph node migratory capacity comparable to ex vivo matured DC. This study shows that in situ maturation offers a simpler and potentially superior method to generate potent immunostimulatory DC for clinical immunotherapy.
This article has been cited by other articles:
|
|
 |
|
  A. Bonehill, A. M.T. Van Nuffel, J. Corthals, S. Tuyaerts, C. Heirman, V. Francois, D. Colau, P. van der Bruggen, B. Neyns, and K. Thielemans Single-Step Antigen Loading and Activation of Dendritic Cells by mRNA Electroporation for the Purpose of Therapeutic Vaccination in Melanoma Patients Clin. Cancer Res., May 15, 2009; 15(10): 3366 - 3375. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 C. M. Long, H. W.M. van Laarhoven, J. W.M. Bulte, and H. I. Levitsky Magnetovaccination as a Novel Method to Assess and Quantify Dendritic Cell Tumor Antigen Capture and Delivery to Lymph Nodes Cancer Res., April 1, 2009; 69(7): 3180 - 3187. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
P. Verdijk, E. H.J.G. Aarntzen, W. J. Lesterhuis, A.C. I. Boullart, E. Kok, M. M. van Rossum, S. Strijk, F. Eijckeler, J. J. Bonenkamp, J. F.M. Jacobs, et al. Limited Amounts of Dendritic Cells Migrate into the T-Cell Area of Lymph Nodes but Have High Immune Activating Potential in Melanoma Patients Clin. Cancer Res., April 1, 2009; 15(7): 2531 - 2540. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 E. L. J. M. Smits, P. Ponsaerts, Z. N. Berneman, and V. F. I. Van Tendeloo The Use of TLR7 and TLR8 Ligands for the Enhancement of Cancer Immunotherapy Oncologist, August 1, 2008; 13(8): 859 - 875. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 S. Adams, D. W. O'Neill, D. Nonaka, E. Hardin, L. Chiriboga, K. Siu, C. M. Cruz, A. Angiulli, F. Angiulli, E. Ritter, et al. Immunization of Malignant Melanoma Patients with Full-Length NY-ESO-1 Protein Using TLR7 Agonist Imiquimod as Vaccine Adjuvant J. Immunol., July 1, 2008; 181(1): 776 - 784. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
Y.-s. Wang, G.-q. Wang, Y.-j. Wen, L. Wang, X.-c. Chen, P. Chen, B. Kan, J. Li, C. Huang, Y. Lu, et al. Immunity against Tumor Angiogenesis Induced by a Fusion Vaccine with Murine {beta}-Defensin 2 and mFlk-1 Clin. Cancer Res., November 15, 2007; 13(22): 6779 - 6787. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 P. Hubert, N. Jacobs, J.-H. Caberg, J. Boniver, and P. Delvenne The cross-talk between dendritic and regulatory T cells: good or evil? J. Leukoc. Biol., October 1, 2007; 82(4): 781 - 794. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
N. Durakovic, K. B. Bezak, M. Skarica, V. Radojcic, E. J. Fuchs, G. F. Murphy, and L. Luznik Host-Derived Langerhans Cells Persist after MHC-Matched Allografting Independent of Donor T Cells and Critically Influence the Alloresponses Mediated by Donor Lymphocyte Infusions J. Immunol., October 1, 2006; 177(7): 4414 - 4425. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
N. Bechetoille, V. Andre, J. Valladeau, E. Perrier, and C. Dezutter-Dambuyant Mixed Langerhans cell and interstitial/dermal dendritic cell subsets emanating from monocytes in Th2-mediated inflammatory conditions respond differently to proinflammatory stimuli J. Leukoc. Biol., July 1, 2006; 80(1): 45 - 58. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
U. Yrlid, S. W. F. Milling, J. L. Miller, S. Cartland, C. D. Jenkins, and G. G. MacPherson Regulation of Intestinal Dendritic Cell Migration and Activation by Plasmacytoid Dendritic Cells, TNF-{alpha} and Type 1 IFNs after Feeding a TLR7/8 Ligand J. Immunol., May 1, 2006; 176(9): 5205 - 5212. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
X.-T. Ma, B. Xu, L.-L. An, C.-Y. Dong, Y.-M. Lin, Y. Shi, and K.-F. Wu Vaccine with {beta}-Defensin 2-Transduced Leukemic Cells Activates Innate and Adaptive Immunity to Elicit Potent Antileukemia Responses Cancer Res., January 15, 2006; 66(2): 1169 - 1176. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
R. M. Prins, N. Craft, K. W. Bruhn, H. Khan-Farooqi, R. C. Koya, R. Stripecke, J. F. Miller, and L. M. Liau The TLR-7 Agonist, Imiquimod, Enhances Dendritic Cell Survival and Promotes Tumor Antigen-Specific T Cell Priming: Relation to Central Nervous System Antitumor Immunity J. Immunol., January 1, 2006; 176(1): 157 - 164. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 M. Gunzer, H. Riemann, Y. Basoglu, A. Hillmer, C. Weishaupt, S. Balkow, B. Benninghoff, B. Ernst, M. Steinert, T. Scholzen, et al. Systemic administration of a TLR7 ligand leads to transient immune incompetence due to peripheral-blood leukocyte depletion Blood, October 1, 2005; 106(7): 2424 - 2432. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
N. Craft, K. W. Bruhn, B. D. Nguyen, R. Prins, J. W. Lin, L. M. Liau, and J. F. Miller The TLR7 Agonist Imiquimod Enhances the Anti-Melanoma Effects of a Recombinant Listeria monocytogenes Vaccine J. Immunol., August 1, 2005; 175(3): 1983 - 1990. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
M. Fassnacht, J. Lee, C. Milazzo, D. Boczkowski, Z. Su, S. Nair, and E. Gilboa Induction of CD4+ and CD8+ T-Cell Responses to the Human Stromal Antigen, Fibroblast Activation Protein: Implication for Cancer Immunotherapy Clin. Cancer Res., August 1, 2005; 11(15): 5566 - 5571. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
G. Rechtsteiner, T. Warger, P. Osterloh, H. Schild, and M. P. Radsak Cutting Edge: Priming of CTL by Transcutaneous Peptide Immunization with Imiquimod J. Immunol., March 1, 2005; 174(5): 2476 - 2480. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
D. W. O'Neill, S. Adams, and N. Bhardwaj Manipulating dendritic cell biology for the active immunotherapy of cancer Blood, October 15, 2004; 104(8): 2235 - 2246. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 S. Adams, D. O'Neill, and N. Bhardwaj Maturation Matters: Importance of Maturation for Antitumor Immunity of Dendritic Cell Vaccines J. Clin. Oncol., September 15, 2004; 22(18): 3834 - 3835. [Full Text] [PDF]
|
|
|
|
|
|
M. Bellone, A. Camporeale, and A. Boni Dendritic Cell Activation Kinetics and Cancer Immunotherapy J. Immunol., March 1, 2004; 172(5): 2727 - 2728. [Full Text] [PDF]
|
|
| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
